Syngenta is accelerating its rollout of nature-inspired biological solutions, backed by new acquisitions, expanded R&D, and a US facility.
Recent moves include acquiring Intrinsyx Bio and integrating Novartis’ natural product assets.
These steps support sustainable farming and strengthen Syngenta’s biologicals pipeline, with several candidates expected to exceed $100 million in annual sales.
